8-K: Cibus Reports Second Quarter Financial Results and Provides First Half Business Update

Cibus announced its second quarter financial results, highlighting progress in commercial agreements, trait development, and regulatory approvals for its gene editing technologies.

Summary

• Cibus reported its financial results for the quarter ended June 30, 2024, and provided a business update for the first half of the year.
• The company secured a fourth customer agreement for its Herbicide Tolerance (HT) traits in rice with FEDEARROZ, building on previous agreements.
• Cibus' wheat platform is now operational, providing access to the largest global grain crop by planted acres.
• The company achieved milestones in developing Advanced Traits, including successful trait edits in Sclerotinia and HT2, and added a third Advanced trait prospect with initial editing for Nutrient Use Efficiency (NUE) in Canola.
• Cibus made progress in the global regulatory landscape, with advances in Canada, the United Kingdom, and a positive vote in the European Union parliament to regulate Cibus gene edited traits similar to conventional breeding.
• The company expanded its intellectual property coverage across 10 plant trait and editing families.
• Cash and cash equivalents were $30.0 million as of June 30, 2024, and are expected to fund operations into the fourth quarter of 2024.
• Research and development (R&D) expenses were $13.0 million for the quarter, compared to $8.4 million in the prior year.
• Selling, general, and administrative (SG&A) expenses were $9.3 million, compared to $11.1 million in the prior year.
• Net loss for the quarter was $28.5 million, compared to $20.5 million in the prior year.
• Net loss per share of Class A common stock was $1.14, compared to $3.05 in the prior year.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is positive progress in technology development, commercial agreements, and regulatory approvals, the financial results show a significant net loss and the need for additional funding, which tempers the overall sentiment.

Positives

• Cibus has expanded its customer base for its herbicide tolerance platform in rice.
• The company has made significant progress in developing advanced traits, including Sclerotinia resistance and Nutrient Use Efficiency.
• Cibus has achieved important regulatory milestones, with gene editing technologies being regulated similarly to conventional breeding in several countries.
• The company has a strong intellectual property portfolio, with expanded coverage across 10 plant trait and editing families.
• Cibus' Trait Machine process is recognized as an innovative product, highlighting its technological advancements.
• The company is actively engaged in discussions with potential seed company partners for its wheat platform.

Negatives

• The company experienced a net loss of $28.5 million for the quarter ended June 30, 2024.
• Research and development expenses increased to $13.0 million for the quarter.
• Royalty liability interest expense related parties increased to $8.7 million for the quarter, a non-cash expense.
• The company's cash position is expected to fund operations only into the fourth quarter of 2024, indicating a need for additional financing.

Risks

• Cibus needs additional near-term funding to finance its activities and faces challenges in obtaining additional capital.
• The company faces competition and challenges to its intellectual property protection.
• There are risks associated with the company's ability to effectively license its productivity traits and sustainable ingredient products.
• Regulatory developments, particularly in the European Union, could impact the company's operations.
• The company is dependent on distributions from Cibus Global, LLC to pay taxes and cover its corporate and overhead expenses.
• There are risks associated with the company's ability to achieve commercial success and the market acceptance of its products.

Future Outlook

Cibus expects its existing cash and cash equivalents to fund planned operating expenses and capital expenditure requirements into the fourth quarter of 2024. The company has several important development and commercial milestone targets for 2024, including expanding its customer base for herbicide tolerance in rice, completing field trials for Pod Shatter Reduction, and advancing its Sclerotinia resistance and HT2 traits.

Management Comments

• The past six months have been some of the most important in our history, marked by the successful progress of many commercial, trait and platform development milestone achievements, and critical developments in the regulatory environment for gene editing technologies, stated Rory Riggs, Co-Founder, Chairman, and CEO of Cibus.
• This year has been about our continued transformation from an R&D-focused company to the first commercial stage gene editing company in agriculture.
• Our focus is on developing traits with specific genetic attributes to drive productivity.

Industry Context

This announcement highlights Cibus' progress in the agricultural biotechnology sector, particularly in gene editing. The company's focus on developing traits for major global row crops aligns with the industry's push for sustainable and efficient agricultural practices. The regulatory advancements in various countries also reflect a growing acceptance of gene editing technologies in agriculture.

Comparison to Industry Standards

• Cibus' focus on gene editing for productivity traits aligns with industry trends, with companies like Corteva Agriscience and Bayer also investing in similar technologies.
• The company's Trait Machine process, which aims for high-throughput gene editing, is comparable to other advanced breeding techniques being developed in the industry.
• Cibus' progress in securing customer agreements for its herbicide tolerance traits in rice is a positive sign, as this is a key area of focus for many agricultural biotech companies.
• The regulatory approvals in Canada, the UK, and the EU are significant, as these regions are important markets for agricultural products and the regulatory landscape is a key factor for commercial success.
• The company's financial results, including the net loss and increased R&D expenses, are typical for a company in the early stages of commercialization in the biotech sector, where significant investments are required for research and development.

Related Party Transactions

• Royalty liability interest expense related parties was $8.7 million for the quarter ended June 30, 2024, compared to $2.6 million in the year-ago period.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the need for additional financing.
• Employees may be impacted by the company's financial performance and any potential cost-saving measures.
• Customers (seed companies) will benefit from the company's technology and trait development.
• Suppliers may be impacted by the company's financial situation and any potential changes in spending.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• Cibus will continue to expand its customer base for its herbicide tolerance platform in Rice.
• The company expects to receive its first European field trial results for PSR in WOSR in 2024.
• Cibus will complete editing and expect greenhouse results for a third mode of action for Sclerotinia resistance.
• The company will complete editing and expect greenhouse results for HT2.
• Cibus expects its Soybean single-cell regeneration platform to be operational and complete initial editing.
• The company expects to enter into initial development and commercial agreements related to Wheat.
• Cibus will continue progress to develop sustainable low carbon ingredients or materials for the consumer packaged goods industry.
• The company plans to launch its first sustainable ingredient in 2025.

Key Dates

Keywords

gene editing, plant traits, herbicide tolerance, rice, wheat, canola, sclerotinia resistance, nutrient use efficiency, regulatory approvals, intellectual property, agricultural biotechnology